Matches in Wikidata for { <http://www.wikidata.org/entity/Q37178916> ?p ?o ?g. }
- Q37178916 description "article científic" @default.
- Q37178916 description "article scientifique" @default.
- Q37178916 description "articolo scientifico" @default.
- Q37178916 description "artigo científico" @default.
- Q37178916 description "artículu científicu espublizáu en 2016" @default.
- Q37178916 description "bilimsel makale" @default.
- Q37178916 description "scientific article published on 14 January 2016" @default.
- Q37178916 description "vedecký článok" @default.
- Q37178916 description "vetenskaplig artikel" @default.
- Q37178916 description "videnskabelig artikel" @default.
- Q37178916 description "vědecký článek" @default.
- Q37178916 description "wetenschappelijk artikel" @default.
- Q37178916 description "wissenschaftlicher Artikel" @default.
- Q37178916 description "наукова стаття, опублікована в січні 2016" @default.
- Q37178916 description "научни чланак" @default.
- Q37178916 description "գիտական հոդված հրատարակված 2016 թվականի հունվարի 14-ին" @default.
- Q37178916 description "مقالة علمية نشرت في 14 يناير 2016" @default.
- Q37178916 name "The significance of PTV dose coverage on cancer control outcomes in early stage non-small cell lung cancer patients treated with highly ablative stereotactic body radiation therapy" @default.
- Q37178916 name "The significance of PTV dose coverage on cancer control outcomes in early stage non-small cell lung cancer patients treated with highly ablative stereotactic body radiation therapy" @default.
- Q37178916 name "The significance of PTV dose coverage on cancer control outcomes in early stage non-small cell lung cancer patients treated with highly ablative stereotactic body radiation therapy" @default.
- Q37178916 type Item @default.
- Q37178916 label "The significance of PTV dose coverage on cancer control outcomes in early stage non-small cell lung cancer patients treated with highly ablative stereotactic body radiation therapy" @default.
- Q37178916 label "The significance of PTV dose coverage on cancer control outcomes in early stage non-small cell lung cancer patients treated with highly ablative stereotactic body radiation therapy" @default.
- Q37178916 label "The significance of PTV dose coverage on cancer control outcomes in early stage non-small cell lung cancer patients treated with highly ablative stereotactic body radiation therapy" @default.
- Q37178916 prefLabel "The significance of PTV dose coverage on cancer control outcomes in early stage non-small cell lung cancer patients treated with highly ablative stereotactic body radiation therapy" @default.
- Q37178916 prefLabel "The significance of PTV dose coverage on cancer control outcomes in early stage non-small cell lung cancer patients treated with highly ablative stereotactic body radiation therapy" @default.
- Q37178916 prefLabel "The significance of PTV dose coverage on cancer control outcomes in early stage non-small cell lung cancer patients treated with highly ablative stereotactic body radiation therapy" @default.
- Q37178916 P1433 Q37178916-B8A15BCE-7F38-44FB-BE25-F35D9EF24BBE @default.
- Q37178916 P1476 Q37178916-DFE4B4AF-E974-44DF-A17A-8F7C1C725134 @default.
- Q37178916 P2093 Q37178916-17DA6572-A54C-48AD-80F7-31DA8291FE41 @default.
- Q37178916 P2093 Q37178916-28C3FE8B-6D4D-4862-8A60-B5D74B73511A @default.
- Q37178916 P2093 Q37178916-45F8A97D-F3D3-4F9F-A913-7BCD7EE6B139 @default.
- Q37178916 P2093 Q37178916-4731B269-0519-4EEF-A466-C5182CF6E8CD @default.
- Q37178916 P2093 Q37178916-619F47CD-87C8-42C6-9FAD-4299824716D6 @default.
- Q37178916 P2093 Q37178916-8965BF2F-874F-49A5-A7B8-A4E9D897AE19 @default.
- Q37178916 P2093 Q37178916-A8D266AD-780E-401A-8849-1AF01089E73F @default.
- Q37178916 P2093 Q37178916-C24ABA3A-2EA1-4E53-9CDB-720543D333C6 @default.
- Q37178916 P2093 Q37178916-C3FC3CA3-45DB-4AC3-91E4-C4DF05AF5182 @default.
- Q37178916 P2860 Q37178916-24A36A83-15E7-4D20-B75A-C5FB37147C7B @default.
- Q37178916 P2860 Q37178916-4AAFB16E-AAD4-419B-9A9C-318D8BC86A01 @default.
- Q37178916 P2860 Q37178916-64FDEC4C-247C-47B7-82D3-E67BB9987093 @default.
- Q37178916 P2860 Q37178916-7A5206DB-12BF-4BA1-8C33-E4308C425961 @default.
- Q37178916 P2860 Q37178916-813E508C-56B9-4BCB-B13F-3ED8821182E1 @default.
- Q37178916 P2860 Q37178916-8E2CCF94-6357-4AE3-8DEB-0F902A747994 @default.
- Q37178916 P2860 Q37178916-9159C1F5-C7E9-4B91-A343-C1862DB7735C @default.
- Q37178916 P2860 Q37178916-95AC225A-12F4-48C2-A02F-B917602A2F2C @default.
- Q37178916 P2860 Q37178916-A0E8102E-3D49-4A70-9107-FAD0EC307D8F @default.
- Q37178916 P2860 Q37178916-A7C27693-CA5D-43F6-9D6B-9DC763CD0A12 @default.
- Q37178916 P2860 Q37178916-AF037A92-2143-4127-9460-0D38617401C7 @default.
- Q37178916 P2860 Q37178916-C92FD902-22DD-4A32-AD11-C6BD0ADA8178 @default.
- Q37178916 P2860 Q37178916-D95777A5-FCA3-4DB7-BF31-8997039FF72A @default.
- Q37178916 P2860 Q37178916-F598C1E5-69BA-467B-BD91-A2F95AC12782 @default.
- Q37178916 P304 Q37178916-3DE2CB70-9521-40CF-8C93-5E4598514AC6 @default.
- Q37178916 P31 Q37178916-2C838AC1-9420-4F25-B36C-4DBB2535025A @default.
- Q37178916 P356 Q37178916-80070D41-D056-42EE-AEAF-FA55D544E930 @default.
- Q37178916 P407 Q37178916-15EFB67A-D5EF-4316-B64C-F68F2A847EC8 @default.
- Q37178916 P433 Q37178916-0DF6C729-FFE4-4F42-AD23-A1F87B102212 @default.
- Q37178916 P478 Q37178916-9E170D00-3576-4312-976E-382EB3A4B38D @default.
- Q37178916 P50 Q37178916-AD6D77F2-4800-49E0-912D-065E70A54E0B @default.
- Q37178916 P50 Q37178916-DC9D36D9-E06D-41A0-AF54-CDA0EF4BDDCB @default.
- Q37178916 P577 Q37178916-A96D3814-BBE2-4D8F-B786-73E8FC13E5C3 @default.
- Q37178916 P698 Q37178916-2ADFC481-2ED4-45BC-8574-26F4E053CF76 @default.
- Q37178916 P921 Q37178916-35A320B8-8F6D-418C-B3CE-3DFA5988AEC1 @default.
- Q37178916 P921 Q37178916-B2D5D5E2-8BCB-49E1-A10F-7D08A477E450 @default.
- Q37178916 P932 Q37178916-9AE44271-4146-4FF6-AE83-02071670F41B @default.
- Q37178916 P356 BJR.20150963 @default.
- Q37178916 P698 26764282 @default.
- Q37178916 P1433 Q15758529 @default.
- Q37178916 P1476 "The significance of PTV dose coverage on cancer control outcomes in early stage non-small cell lung cancer patients treated with highly ablative stereotactic body radiation therapy" @default.
- Q37178916 P2093 "Chul Lee" @default.
- Q37178916 P2093 "Darlene Veruttipong" @default.
- Q37178916 P2093 "Jason Wang" @default.
- Q37178916 P2093 "John Hegde" @default.
- Q37178916 P2093 "Michael Steinberg" @default.
- Q37178916 P2093 "Minsong Cao" @default.
- Q37178916 P2093 "Nzhde Agazaryan" @default.
- Q37178916 P2093 "Percy Lee" @default.
- Q37178916 P2093 "Stephen Tenn" @default.
- Q37178916 P2860 Q33928404 @default.
- Q37178916 P2860 Q34010065 @default.
- Q37178916 P2860 Q36866000 @default.
- Q37178916 P2860 Q44380483 @default.
- Q37178916 P2860 Q46119836 @default.
- Q37178916 P2860 Q47560788 @default.
- Q37178916 P2860 Q47604097 @default.
- Q37178916 P2860 Q48964621 @default.
- Q37178916 P2860 Q51061126 @default.
- Q37178916 P2860 Q51611763 @default.
- Q37178916 P2860 Q51773591 @default.
- Q37178916 P2860 Q52144520 @default.
- Q37178916 P2860 Q53299557 @default.
- Q37178916 P2860 Q80587769 @default.
- Q37178916 P304 "20150963" @default.
- Q37178916 P31 Q13442814 @default.
- Q37178916 P356 "10.1259/BJR.20150963" @default.
- Q37178916 P407 Q1860 @default.
- Q37178916 P433 "1059" @default.
- Q37178916 P478 "89" @default.
- Q37178916 P50 Q110644136 @default.
- Q37178916 P50 Q61093657 @default.